LLY

901.22

-1.59%↓

JNJ

240.65

+0.23%↑

ABBV

211.04

+2.18%↑

NVS

150.37

-0.4%↓

MRK

119.27

+0.14%↑

LLY

901.22

-1.59%↓

JNJ

240.65

+0.23%↑

ABBV

211.04

+2.18%↑

NVS

150.37

-0.4%↓

MRK

119.27

+0.14%↑

LLY

901.22

-1.59%↓

JNJ

240.65

+0.23%↑

ABBV

211.04

+2.18%↑

NVS

150.37

-0.4%↓

MRK

119.27

+0.14%↑

LLY

901.22

-1.59%↓

JNJ

240.65

+0.23%↑

ABBV

211.04

+2.18%↑

NVS

150.37

-0.4%↓

MRK

119.27

+0.14%↑

LLY

901.22

-1.59%↓

JNJ

240.65

+0.23%↑

ABBV

211.04

+2.18%↑

NVS

150.37

-0.4%↓

MRK

119.27

+0.14%↑

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

535.57 -1.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

528.86

Max

544.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	26M 364M
Pardavimai	-9.3M 790M
P/E Sektoriaus vid.	18.702 57.05
Pelno marža	46.102
Darbuotojai	1,400
EBITDA	61M 524M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+11.83% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 23B
Ankstesnė atidarymo kaina	536.94
Ankstesnė uždarymo kaina	535.57

Naujienos nuotaikos

By Acuity

50%

167 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

292.345 / 309.245 Palaikymas ir pasipriešinimas

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-25 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Infosys Agrees to Acquire Stratus

2026-03-25 23:58; UTC

Uždarbis

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

2026-03-25 23:58; UTC

Uždarbis

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

2026-03-25 23:41; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

2026-03-25 23:41; UTC

Uždarbis

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

2026-03-25 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Declines on Possible Technical Correction -- Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

2026-03-25 21:58; UTC

Rinkos pokalbiai

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

2026-03-25 21:37; UTC

Rinkos pokalbiai

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

2026-03-25 21:14; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

2026-03-25 21:13; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

2026-03-25 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

2026-03-25 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-25 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-03-25 20:33; UTC

Įsigijimai, susijungimai, perėmimai

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

2026-03-25 20:31; UTC

Uždarbis

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

11.83% į viršų

12 mėnesių prognozė

Vidutinis 594.75 USD 11.83%

Aukščiausias 705 USD

Žemiausias 471 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

292.345 / 309.245Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

167 / 350 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.